Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

USA - NASDAQ:SABS - US78397T2024 - Common Stock

3.02 USD
-0.01 (-0.33%)
Last: 10/28/2025, 5:43:30 PM
3.02 USD
0 (0%)
After Hours: 10/28/2025, 5:43:30 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SABS. SABS was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of SABS have multiple concerns. SABS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SABS has reported negative net income.
In the past year SABS has reported a negative cash flow from operations.
SABS had negative earnings in 4 of the past 5 years.
In multiple years SABS reported negative operating cash flow during the last 5 years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

SABS has a worse Return On Assets (-122.99%) than 80.52% of its industry peers.
With a Return On Equity value of -308.38%, SABS is not doing good in the industry: 71.16% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -122.99%
ROE -308.38%
ROIC N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SABS has more shares outstanding than it did 1 year ago.
SABS has a worse debt/assets ratio than last year.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -10.05, we must say that SABS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.05, SABS is not doing good in the industry: 72.85% of the companies in the same industry are doing better.
SABS has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
SABS's Debt to Equity ratio of 0.27 is on the low side compared to the rest of the industry. SABS is outperformed by 69.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -10.05
ROIC/WACCN/A
WACC8.56%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

SABS has a Current Ratio of 0.87. This is a bad value and indicates that SABS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.87, SABS is doing worse than 88.58% of the companies in the same industry.
SABS has a Quick Ratio of 0.87. This is a bad value and indicates that SABS is not financially healthy enough and could expect problems in meeting its short term obligations.
SABS has a worse Quick ratio (0.87) than 88.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.75% over the past year.
SABS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.87%.
Measured over the past years, SABS shows a very negative growth in Revenue. The Revenue has been decreasing by -72.10% on average per year.
EPS 1Y (TTM)30.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.97%
Revenue 1Y (TTM)-95.87%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SABS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.44% on average per year.
SABS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.46% yearly.
EPS Next Y38.16%
EPS Next 2Y29.81%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y130.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

SABS's earnings are expected to grow with 23.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.81%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SABS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (10/28/2025, 5:43:30 PM)

After market: 3.02 0 (0%)

3.02

-0.01 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners18.18%
Inst Owner Change15.77%
Ins Owners13.76%
Ins Owner Change13.16%
Market Cap31.44M
Revenue(TTM)114.70K
Net Income(TTM)-37055200
Analysts85
Price Target9.01 (198.34%)
Short Float %7.76%
Short Ratio2.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-34.25%
Max EPS beat(2)46.7%
EPS beat(4)1
Avg EPS beat(4)2.11%
Min EPS beat(4)-34.25%
Max EPS beat(4)46.7%
EPS beat(8)4
Avg EPS beat(8)-42.48%
EPS beat(12)7
Avg EPS beat(12)-31.03%
EPS beat(16)10
Avg EPS beat(16)-39.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.99%
PT rev (3m)-27.89%
EPS NQ rev (1m)13.87%
EPS NQ rev (3m)11.54%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 274.09
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.62
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.96
OCFYN/A
SpS0.01
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.99%
ROE -308.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -10.05
F-Score1
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)828.01%
Cap/Sales(3y)14.46%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.97%
EPS Next Y38.16%
EPS Next 2Y29.81%
EPS Next 3Y23.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-95.87%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y130.46%
EBIT growth 1Y8.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-110.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.79%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SABS.


Can you provide the valuation status for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


How profitable is SAB BIOTHERAPEUTICS INC (SABS) stock?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 0 / 10.


How financially healthy is SAB BIOTHERAPEUTICS INC?

The financial health rating of SAB BIOTHERAPEUTICS INC (SABS) is 0 / 10.